Ann: ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH, page-13

Ya and the beauty if you remember is that Tokyo is home to the head office of Chugai Pharmaceutical Co. Ltd who are based in Chuo City Tokyo......

And remembering also the Chugai Pharmaceutical Co. Ltd is 62% owned by Hoffmann Roche and who through Verastem recently entered into a collaboration agreement with Chungai ( refer my previous post excerpt below ) for its Defactnib candidate which is of course another FAK inhibitor used for Pancreatic and other fibrous cancer tumours

Currently Veristem's market Capitalization is y sitting around USD $463.5 million ( AUD $610 million ) as a comparison.

" Verastem has also recently entered into a collaboration with Defactnib with Chugai Pharmaceutical Co. Ltd , a Japanese Pharma who is 62% owned by Hoffmann Roche and is valued at US$75 billion. Hoffmann of course is held by Roche Holdings AG which is in turn valued at US $235 billion. "